HeartBeam’s heart‑attack assessment technology joins FDA’s TAP Pilot after Breakthrough Device designation
HeartBeam Inc. announced that the FDA accepted its 3‑D ECG heart‑attack assessment platform into the Total Product Life Cycle Advisory Program (TAP) Pilot. The acceptance follows a Breakthrough Device Designation granted earlier in the month. TAP will assign FDA advisors and facilitate early dialogue with payers and patient groups. The company plans to start enrolling patients in a multicenter pivotal trial in the first quarter of 2027, pending regulatory alignment.
Why it matters
The TAP Pilot gives HeartBeam structured regulatory support and early payer engagement, which could speed reimbursement discussions and market entry for the heart‑attack indication. Investor exposure to the company may change once patient enrollment begins and the pivotal study data become available.
Key facts
- 1The FDA accepted HeartBeam’s 3‑D ECG heart‑attack assessment technology into the TAP Pilot program. stocktitan.net
- 2HeartBeam received FDA Breakthrough Device Designation for the same technology earlier in the month. stocktitan.net
- 3TAP assigns dedicated FDA advisors and connects developers with patient advocacy groups, provider organizations, and health‑insurance payers. stocktitan.net
- 4HeartBeam intends to begin patient enrollment for a multicenter pivotal study in the first quarter of 2027, after seeking FDA alignment on the study design. investing.com
- 5The HeartBeam System is currently cleared only for arrhythmia assessment; its use for heart‑attack detection remains investigational. stocktitan.net
- 6HeartBeam is evaluating eligibility for the RAPID coverage pathway announced by CMS and the FDA in April 2026. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.